Valuation
- Market cap
- 795,000
- Revenue TTM
- $20,180,000
- Net income TTM
- $390,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 1.93%
- Debt to equity
- 0.00
Trading
- Volume
- 166,100
- Avg volume
- 131,924
- Day's range
- $0.01 – $0.01
- Shares out
- 132,530,000
- Stochastic %K
- 0%
- Beta
- -1.37
- Analysts
- —
- Price target
- $68.75
Company profile
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San...
Show more
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 550 1900
- Website
- https://www.evofem.com
- Address
- 7770 Regents Rd, Suite 113-618, San Diego, United States
Latest news
No headlines yet.
